Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. 薬物名(臨床試験情報から抽出) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1200mg Cannabidiol by capsules twice daily1件: Cannabidiol1件: Cannabidiol 💬2件: CNR1,
CNR2 💬
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬1件: 46 💬
2400mg Cannabidiol by capsules twice daily1件: Cannabidiol1件: Cannabidiol 💬2件: CNR1,
CNR2 💬
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬1件: 46 💬
3Abacavir 300mg twice daily1件: Abacavir1件: Abacavir 💬--1件: 265 💬
4ACTHAR Gel 40 units twice weekly1件: Corticotropin1件: Corticotropin 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 84 💬
5ACTHAR Gel 80 units twice weekly.1件: Corticotropin1件: Corticotropin 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 84 💬
6All subjects will receive maraviroc 300mg orally twice a day for 6 weeks1件: Maraviroc1件: Maraviroc 💬1件: CCR5 💬11件: Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Toxoplasmosis, Viral carcinogenesis, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬1件: 84 💬
7AZLI 75 mg two times a day (BID)/ three times a day (TID)----1件: 299 💬
8AZLI 75 mg two times a day (BID)/three times a day (TID)----1件: 299 💬
9Budesonide 0.5mg orodispersible tablet twice daily1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
10Budesonide 1mg orodispersible tablet twice daily1件: Budesonide1件: Budesonide 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98 💬
11Burosumab
(Burosumab-twza)
1件: Burosumab (burosumab-twza)1件: Burosumab (Burosumab-twza) 💬1件: FGF23 💬11件: Breast cancer, Calcium signaling pathway, Gastric cancer, MAPK signaling pathway, Melanoma, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton 💬1件: 238 💬
12Chinese herbal concoction twice a day for 6 months----1件: 60 💬
13Colistimethate 75 mg inhaled two times daily1件: Colistimethate---1件: 299 💬
14Crysvita (burosumab-twza) Treatment1件: Burosumab (burosumab-twza)1件: Burosumab (Burosumab-twza) 💬1件: FGF23 💬11件: Breast cancer, Calcium signaling pathway, Gastric cancer, MAPK signaling pathway, Melanoma, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton 💬1件: 238 💬
15ETD001 multiple twice daily doses----1件: 299 💬
16Fampridine-SR b.i.d. (Twice Daily)1件: Dalfampridine1件: Dalfampridine 💬4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬
4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬1件: 13 💬
17Gentamicin infusions twice a week for six months1件: Gentamicin1件: Gentamicin 💬--1件: 113 💬
18High dose BIBF 1120 twice daily----1件: 85 💬
19Intermediate dose BIBF 1120 twice daily----1件: 85 💬
20JNJ-54781532 75 mg twice daily----1件: 97 💬
21Low dose BIBF 1120 twice daily----1件: 85 💬
22Mesalamine Twice-Daily1件: Mesalazine1件: Mesalamine 💬--1件: 97 💬
23Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH)1件: Tripterygium wilfordii whole---1件: 66 💬
24Mycophenolate mofetil orally 1000 mg twice a day (BID)2件: Mycophenolate mofetil,
Mycophenolic acid
2件: Mycophenolate mofetil ,
Mycophenolic acid 💬
2件: IMPDH1,
IMPDH2 💬
4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬1件: 222 💬
25Part 1 Levulan surface application twice----1件: 34 💬
26Part 1 Levulan surface application twice with microneedling----1件: 34 💬
27PXT3003 Dose 2 (equivalent to twice Dose 1)----1件: 10 💬
28TOBI™ Podhaler™ 112 mg inhaled twice daily----1件: 299 💬
29Tofacitinib 5 mg twice daily1件: Tofacitinib1件: Tofacitinib 💬4件: JAK1,
JAK2,
JAK3,
TYK2 💬
37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 84 💬
30Treatment of MTX and TwHF----1件: 46 💬
31Treatment of TwHF----1件: 46 💬
32Tripterygium wilfordii (TW)1件: Tripterygium wilfordii whole---2件: 66, 222 💬
33Tripterygium wilfordii Hook F (TwHF)1件: Tripterygium wilfordii whole---1件: 46 💬
34TW----1件: 222 💬
35TwHF----1件: 46 💬
36Twice-daily dosage with 0.5% cyclosporine-A eyedrops1件: Cyclosporine1件: Cyclosporine 💬5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬
33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 90 💬